News
When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...
Viking Therapeutics ( VKTX -43.72%) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what ...
The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.
Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.
Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...
We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...
17h
Zacks.com on MSNViking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...
Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.
Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results